ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SUPN vs PGEN // EV/EBITDA & P/E VALUATION

Supernus Pharmaceuticals Inc. (NASDAQ) VS. Precigen Inc. (NASDAQ) • 15-METRIC TALLY: SUPN 7 — PGEN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. PGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SUPN PGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 89.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -4.50% -35.00% +30.50 SUPN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 1.89% -3.78% +5.67 SUPN /fcf-yield <GO>
Operating Margin -8.70% -60.00% +51.30 SUPN /operating-margins <GO>
Net Profit Margin -5.40% -60.00% +54.60 SUPN /net-margins <GO>
Revenue Growth (YoY) 8.60% 146.70% -138.10 PGEN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.84 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 SUPN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.5 50.3 +0.22 SUPN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.88 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 22.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.43B $2.38B $54.7M SUPN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SUPN REV PGEN REV SUPN GROSS % PGEN GROSS % SUPN FCF PGEN FCF
FY 2025 $719.0M $9.7M 89.6% — $46.0M -$89.8M
FY 2024 $661.8M $3.9M 88.2% — $171.2M -$76.8M
FY 2023 $607.5M $6.2M — — $83.7M -$66.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
PGEN // BETA —